Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 13Withdrawn 4Terminated 3Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1Dermatologic 1

Conditions

Skin Neoplasms 1Pancreatic Diseases 1Multiple Myeloma 1Carcinoma, Basal Cell 1Carcinoma 1Basal Cell Nevus Syndrome 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × OTHER × sonidegib × Clear all
NCT01431794 2020-01-22

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Terminated
23 enrolled 10 charts
Gastrointestinal

Carcinoma, Pancreatic Diseases

NCT02303041 2019-01-29

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Stanford University

Phase 2 Terminated
10 enrolled 11 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Skin Neoplasms

NCT02254551 2017-02-16

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Terminated
7 enrolled 6 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡